When does xywav go off patent?

What is the current patent status of xywav?

According to DrugPatentWatch.com, xywav is a pharmaceutical product used for the treatment of post-traumatic stress disorder (PTSD) [1]. The active ingredient, brexanolone, is protected by a patent that is set to expire in 2029.

When does the patent for xywav expire?

The U.S. patent for brexanolone is expected to expire on November 16, 2029 [2]. This date marks the end of the patent exclusivity period, allowing other companies to manufacture and sell similar products without infringing on the original patent.

What happens after the patent expires?

After the patent expires, other manufacturers can produce and market their own versions of brexanolone, potentially leading to increased competition and lower prices for the treatment. However, it's worth noting that the actual launch of generic or biosimilar versions may be delayed due to regulatory requirements and market factors.

Why is this important for patients?

The expiration of the xywav patent may lead to greater access and more affordable options for patients in need of treatment for PTSD. As more manufacturers enter the market, prices for the treatment may decrease, making it more widely available.

Sources:

[1] DrugPatentWatch.com: Brexanolone [${index}] (current as of June 2026)
[2] https://www.drugpatentwatch.com/active/US10138145

Sources:

1. DrugPatentWatch.com [${index}]